Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02004678
Recruitment Status : Completed
First Posted : December 9, 2013
Last Update Posted : December 24, 2018
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

Brief Summary:
DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo‑controlled, randomized, 2‑part, sequential, single ascending dose, single center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral dose of DS‑1150b in healthy subjects and subjects with Type 2 Diabetes Mellitus.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: DS-1150b Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
Study Start Date : September 2013
Actual Primary Completion Date : September 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Cohort 1, 7.5 mg DS-1150b

Dosing will occur over two periods. Subjects will receive either

  • a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or
  • a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.
Drug: DS-1150b
Other: Placebo
Cohort 2, 15 mg DS-1150b

Dosing will occur over two periods. Subjects will receive either

  • a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or
  • a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2.
Drug: DS-1150b
Other: Placebo



Primary Outcome Measures :
  1. area under curve (AUC) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.

  2. maximum plasma concentration (Cmax) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.

  3. terminal elimination half-life (t1/2) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.

  4. time to reach maximum plasma concentration (Tmax) [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effect of single oral doses of DS-1150b on glucose excursion (incremental glucose AUC0-3h) after an OGTT in subjects with Type 2 Diabetes Mellitus.


Secondary Outcome Measures :
  1. measure the effects on Insulin and C-peptide Levels [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effects of single oral dose of DS-1150b on insulin and C-peptide levels in subjects with Type 2 Diabetes Mellitus.

  2. number of patients experiencing adverse events [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.

  3. measure the effects on glucagon Levels [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the effects of single oral dose of DS-1150b on glucagon levels in subjects with Type 2 Diabetes Mellitus.

  4. number of patients experiencing laboratory adverse events [ Time Frame: 24 days, Day -5 to Day 19 ]
    To assess the safety and tolerability of single oral dose of DS-1150b in subjects with Type 2 diabetes mellitus.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

All Subjects:

  • All women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. Women must be of non-childbearing potential, either:

    • Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dose administration).
    • <60 years of age and naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dose administration, with a follicle stimulating hormone (FSH) level at screening of

      ≥40 mIU/mL.

    • >60 years of age and naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dose administration.
  • Male subjects have to agree to contraception (condom with spermicide) in addition to having their female partner (if of child-bearing potential) use another form of contraception (eg, an intrauterine device, diaphragm with spermicide, oral until 12 weeks following the last dose administration. In addition, the male subjects must not donate sperm after the study for a period of 12 weeks.
  • Subjects must give written informed consent to participate in the study prior to screening.
  • Subjects must be in good health as determined by screening medical history, physical examination findings, vital signs measurement, ECGs, serum chemistry, hematology, virology (ie, HIV, HBV, and HCV at screening only), and urinalysis performed at screening and on Day -1.
  • Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges from 10 days before the first dose and throughout the study.
  • All subjects must have a negative fecal occult blood test.

Part B (Type 2 Diabetes Mellitus):

  • Men and women who are not of childbearing potential, 18 years to 60 years of age, inclusive.
  • A BMI of 25 kg/m2 to 38 kg/m2, inclusive.
  • Diagnosis of Type 2 DM for a minimum of 3 months prior to first dose.
  • Subjects should be either:

    • On metformin alone with a hemoglobin A1c (HBA1c) value between 7% to 9.5%, inclusive.
    • Treatment naïve or treatment free from any antidiabetic treatment for at least 3 months prior to screening with a HBA1c value between 7% to 10%, inclusive.
  • Subjects with fasting plasma glucose ≥100 mg/dL and ≤250 mg/dL, for screening and on Day -1.

Exclusion Criteria:

All Subjects:

  • History of gastrointestinal ulcer or erosion, or rhabdomyolysis within 6 months of dose administration.
  • Subjects with laboratory results outside the normal range, if considered clinically significant by the Investigator.
  • Subjects with serum K above the ULN of the clinical laboratory's reference range at screening and on Day -1.
  • Subjects with CPK above the ULN at screening and on Day -1.
  • Subjects with lactate above the ULN at screening and on Day -1.
  • Subjects with QTcF interval duration >450 msec, obtained as an average from the 3 ECG recorder's measurements on the triplicate screening ECGs (3 ECGs in close succession at least 1 min apart) taken after at least 10 minutes of quiet rest in supine position.
  • Subjects with abnormal waveform morphology on any of the ECGs at the screening and on Day -1 that would preclude accurate measurement of the QT interval duration.
  • History of any serious disorder, including cardiovascular, hematologic, pulmonary, hepatic, renal, gastrointestinal, skeletal, connective tissue disease, uncontrolled endocrine/metabolic other than subjects with Type 2 DM in Part B, oncologic (within the last 5 years), neurologic, and psychiatric diseases, or any disorder that may prevent the successful completion of the study.
  • Subjects who have had physical trauma, surgery or a significant illness within 4 weeks prior to the first dose.
  • Donated or lost >500 mL of blood or plasma within 3 months prior to the first dose on Day 1.
  • Participated in a clinical study involving administration of an investigational drug (new chemical entity), or a marked drug within the 30 days prior to administration of the first dose.

Part B (Type 2 Diabetes Mellitus)

  • History of Type 1 diabetes and/or history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
  • History of severe microvascular or macrovascular complications of Type 2 DM, including proliferative retinopathy, macroalbuminuria, peripheral neuropathy, ischemic heart disease, stroke, and peripheral vascular disease.
  • History of diabetic neuropathy.
  • Need for any concomitant medication that is moderate or strong CYP inhibitors including CYP3A4, CYP2D6, CYP2C9, and CYP2C19, or P-gp inhibitor. Need for other antidiabetic drugs except for metformin. Other common concomitant medications in diabetic patients may be allowed (eg, aspirin and thyroid hormones) upon agreement between the Sponsor and the PI.
  • Subjects with liver function of ALT and AST above 1.25 × ULN, or total bilirubin above ULN at screening and on Day -1.
  • Moderate or severe renal dysfunction, defined as eGFR (using MDRD equation) <60 mL/min.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02004678


Locations
Layout table for location information
United States, Florida
Clinical Pharmacology of Miami, Inc.
Miami, Florida, United States
Sponsors and Collaborators
Daiichi Sankyo, Inc.

Layout table for additonal information
Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT02004678     History of Changes
Other Study ID Numbers: DS1150-A-U101
First Posted: December 9, 2013    Key Record Dates
Last Update Posted: December 24, 2018
Last Verified: December 2013
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
URL: https://vivli.org/ourmember/daiichi-sankyo/

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases